This has led to the proposal of non-pharmacological strategies focused on lifestyles and pharmacological therapies (such as the administration of non-steroidal anti-inflammatory drugs, anti-TNF-α antibody therapy, dextromethrophan and pioglitazone) focused on preventing or delaying the onset and rate of PD progression by decreasing neuroinflammation [78]. The gene discussed is TNF; the disease is Parkinson disease.